Best Cell Therapy CDMOs by Signal Score

← All Cell Therapy CDMOs Best Clean FDA History Commercial Scale
Region: USA Europe Asia
10
CDMOs tracked
10
Fully scored
9
With FDA records
29
FDA inspections
72
EMA/MHRA GMP certs

Cell therapy CDMOs manufacture living products — CAR-T, TCR, NK, and stem-cell therapies — where the process is the product. Autologous programs add patient-scheduling and chain-of-identity demands that allogeneic, batch-based programs avoid.

The right cell therapy CDMO depends on autologous vs allogeneic experience, vector sourcing, closed-system processing, and cold-chain logistics. The rankings below score each CDMO on FDA inspections, GMP certification, clinical activity, and capacity.

FDA inspection outcomes across these CDMOs: 14 NAI (no action), 14 VAI (voluntary action), 1 OAI (official action). Leading inspection & GMP sites: United States (26), Germany (23), Denmark (18), Austria (9), Ireland (6).

Last updated 2026-07-11. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.

# CDMO Signal Score Quality FDA · GMP Capacity Programs
1
BMS
Bristol Myers Squibb (CGT Mfg)
Bothell, WA · Warren, NJ
 90.8 97.0 6 insp · 2 GMP — 583 programs
2
COH
City of Hope (T Cell Manufacturing)
Duarte, CA
 83.8 96.8 3 insp · 0 GMP — 211 programs
3
MK
Merck KGaA / MilliporeSigma (CDMO)
Darmstadt, DE · St. Louis, MO
 81.8 98.6 2 insp · 2 GMP — 22 programs
4
AG
AGC Biologics
Longmont, CO · Milan, IT · Copenhagen, DK · Chiba, JP
 80.6 99.9 2 insp · 23 GMP Available 2 programs
5
TK
Takeda
Boston, MA · Zurich, CH
 80.5 99.3 4 insp · 18 GMP — 100 programs
6
BY
Bayer (Cell Therapy Mfg)
Berkeley, CA
 79.2 86.9 8 insp · 17 GMP — 126 programs
7
CS
Cedars-Sinai Biomanufacturing
Los Angeles, CA
 78.9 100.0 1 insp · 0 GMP — 34 programs
8
Lonza
Basel, Switzerland
 78.2 95.1 2 insp · 8 GMP — 1 programs
9
MB
Miltenyi Biotec
Bergisch Gladbach, Germany
 74.6 100.0 0 insp · 2 GMP — 8 programs
10
NR
National Resilience
San Diego, CA · Boston, MA · RTP, NC · Philadelphia, PA
 73.4 97.7 1 insp · 0 GMP Available 9 programs
How we score CDMOs →

What to evaluate in a Cell Therapy CDMO

Autologous vs allogeneic
Autologous needs per-patient scheduling, chain-of-identity, and short turnaround; allogeneic needs scalable batch processing and a master cell bank strategy. Pick a CDMO proven in your model.
Vector & raw materials
Most cell therapies need a viral vector. Confirm whether the CDMO makes vector in-house or coordinates an external supplier, and how that affects timelines.
Closed-system & cleanrooms
Closed, automated processing reduces contamination risk and labor. Ask about cleanroom grade, automation platforms, and parallel-suite capacity.
Cold chain & logistics
Cryopreservation and chain-of-custody are critical for living cells. Evaluate the CDMO's cold-chain and apheresis-to-infusion logistics.

Cell Therapy CDMOs — Frequently Asked Questions

Who are the top Cell Therapy CDMOs?
By CDMO Signal's independent Signal Score, the top-ranked Cell Therapy CDMOs include Bristol Myers Squibb (CGT Mfg), City of Hope (T Cell Manufacturing), Merck KGaA / MilliporeSigma (CDMO). See the full ranked table above — scored on FDA, clinical, financial, and capacity data.
How many Cell Therapy CDMOs have FDA inspection records?
CDMO Signal tracks 9 Cell Therapy CDMOs with FDA inspection records and 72 EMA/MHRA GMP certificates across the group.
What should I look for in a cell therapy CDMO?
Match the CDMO to your model: autologous needs chain-of-identity and fast turnaround; allogeneic needs scalable batch processing. Confirm vector sourcing, closed-system processing, cold-chain logistics, and a clean FDA and EMA/MHRA record.
Do cell therapy CDMOs make their own viral vectors?
Some do in-house; others coordinate an external vector supplier. In-house vector can shorten timelines and simplify supply, but a strong external partner is common. Check each profile's modality coverage above.
Related modalities
Lentiviral Vector CDMOs CAR-T CDMOs Gene Editing CDMOs
Other Modalities
AAV CAR-T Lentiviral mRNA/LNP Plasmid DNA Biologics Oligo/ASO Adenoviral Gene Editing Exosome Recombinant Proteins ADC Gene Therapy Cell & Gene Therapy